 |
11 Diseases |  |
2 Trials |
|
2 Trials |  |
424 News |  |
| «1234 |
- | aldoxorubicin (INNO-206) / LadRx
Trial completion, Metastases: Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer (clinicaltrials.gov) - Jun 26, 2013
P2, N=14, Completed, Sponsor: CytRx
Active, not recruiting --> Completed
- | aldoxorubicin (INNO-206) / LadRx
Trial completion, Metastases: Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Feb 10, 2013
P1, N=24, Completed, Sponsor: CytRx
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | aldoxorubicin (INNO-206) / LadRx
New P1 trial, Metastases: Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Oct 11, 2012
P1, N=12, Active, not recruiting, Sponsor: CytRx
- | aldoxorubicin (INNO-206) / ImmunityBio
New P1 trial, Metastases: Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Aug 26, 2012
P1, N=15, Completed, Sponsor: CytRx
- | aldoxorubicin (INNO-206) / LadRx
New P2 trial, Metastases: Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer (clinicaltrials.gov) - Apr 17, 2012
P2, N=14, Completed, Sponsor: CytRx
- aldoxorubicin (INNO-206) / LadRx
Trial withdrawal: INNO-206 in Patients With Small Cell Lung Cancer (SCLC) (clinicaltrials.gov) - Feb 7, 2012
P2, N=0, Withdrawn, Sponsor: CytRx
Active, not recruiting --> Completed Terminated --> Withdrawn
- ||||| aldoxorubicin (INNO-206) / LadRx
New P2 trial, Metastases: Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jan 19, 2012
P2, N=105, Active, not recruiting, Sponsor: CytRx